SuperworthBenitec Biopharma EPS BNTC
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$0.98
- Latest quarter, Q4 FY26
- −$0.26
- Fiscal year 2026
- −$0.98
Benitec Biopharma's earnings per share was −$0.98 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was −$0.26.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$0.98 | n/a |
| FY2025 | −$1.03 | n/a |
| FY2024 | −$6.52 | n/a |
| FY2023 | −$16.82 | n/a |
| FY2022 | −$37.91 | n/a |
| FY2021 | −$78.20 | n/a |
| FY2020 | −$135.49 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$0.26 | n/a | −$0.98 | |
| Q3 FY26 | −$0.24 | n/a | −$0.93 | |
| Q2 FY26 | −$0.26 | n/a | −$1.07 | |
| Q1 FY26 | −$0.22 | n/a | −$1.07 | |
| Q4 FY25 | −$0.21 | n/a | −$1.03 | |
| Q3 FY25 | −$0.38 | n/a | −$1.42 | |
| Q2 FY25 | −$0.26 | n/a | −$1.27 | |
| Q1 FY25 | −$0.18 | n/a | −$3.65 | |
| Q4 FY24 | −$0.60 | n/a | −$6.52 | |
| Q3 FY24 | −$0.23 | n/a | −$8.75 | |
| Q2 FY24 | −$2.64 | n/a | −$11.19 | |
| Q1 FY24 | −$3.05 | n/a | −$11.89 |
Against its peers
Companies in Drug Manufacturers - General nearest Benitec Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BNTCBenitec Biopharma | −$0.98 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Benitec Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.